Trucut Biopsy of 2 Lesions in Same Breast at Chughtai Lab

Introduction to Trucut Biopsy of 2 Lesions in Same Breast at Chughtai Lab

A Trucut biopsy, also known as a core needle biopsy, is a highly precise diagnostic procedure used to obtain tissue samples from suspicious breast masses. When a patient presents with multiple abnormal areas, performing a Trucut biopsy of 2 lesions in the same breast is essential to determine whether the lesions are benign, pre-malignant, or malignant. This procedure is critical for guiding therapeutic decisions, especially when distinguishing between multifocal breast disease (multiple tumors within the same quadrant) and multicentric breast disease (multiple tumors in different quadrants of the same breast). At Chughtai Lab, this specialized interventional pathology procedure is performed under strict clinical protocols to ensure maximum diagnostic yield and patient safety.

The procedure utilizes a specialized, hollow Trucut needle assembly. Under local anesthesia, the needle is advanced into each target lesion, typically under high-resolution ultrasound guidance, to extract solid cores of tissue. Unlike fine-needle aspiration (FNA), which only retrieves individual cells, a core needle biopsy preserves the histological architecture of the tissue. This allows consultant pathologists at Chughtai Lab to evaluate the spatial arrangement of cells, identify invasion into surrounding stroma, and perform essential immunohistochemical (IHC) staining if malignancy is detected. Evaluating two distinct lesions within the same breast is clinically vital because different masses can exhibit completely different pathological profiles, a phenomenon known as intratumoral and interlesional heterogeneity. Accurate characterization of both lesions prevents underdiagnosis and ensures that the subsequent surgical or oncological treatment plan is perfectly tailored to the patient\’s specific disease profile.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to minimize complications such as hematoma formation and to ensure a smooth, comfortable procedure. Patients scheduled for a Trucut biopsy of 2 lesions in the same breast at Chughtai Lab should adhere to the following medical guidelines:

• Medication Review: Inform the clinical team of all current medications. Anticoagulants and antiplatelet agents (such as aspirin, clopidogrel, warfarin, or low-molecular-weight heparin) must be discussed with the referring physician. These may need to be temporarily discontinued 3 to 5 days prior to the biopsy to reduce the risk of post-procedure bleeding.
• Hygiene and Cosmetics: On the day of the procedure, bathe or shower thoroughly. Do not apply any deodorants, perfumes, talcum powders, creams, or lotions to the breast area or underarms, as these substances can contain metallic particles that interfere with high-resolution ultrasound imaging.
• Apparel: Wear comfortable, loose-fitting, two-piece clothing. A supportive, non-wired bra should be worn or brought to the clinic, as it helps hold the post-procedure dressing firmly in place and minimizes breast movement, reducing post-biopsy discomfort.
• Dietary Instructions: There are generally no strict fasting requirements for a local anesthetic biopsy. A light meal prior to the appointment is recommended to prevent dizziness or vasovagal episodes during the procedure.
• Medical Records: Bring all previous diagnostic imaging reports, including mammograms, breast ultrasounds, and breast MRI scans, along with the referring physician\’s prescription.

During the Procedure

The Trucut biopsy of two distinct breast lesions is performed in a sterile, controlled environment by an experienced interventional radiologist or pathologist. The step-by-step clinical workflow includes:

• Patient Positioning: The patient lies in a comfortable supine or semi-lateral position on the examination table, with the ipsilateral arm raised above the head to expose the breast and axillary region fully.
• Lesion Localization: High-resolution ultrasound is performed to re-identify and precisely map the coordinates of both target lesions within the breast. This real-time imaging ensures that the biopsy needle is placed accurately within the solid components of each lesion, avoiding necrotic centers or adjacent blood vessels.
• Aseptic Preparation and Anesthesia: The skin overlying the breast is cleaned with an antiseptic solution (such as chlorhexidine or povidone-iodine), and sterile drapes are applied. A local anesthetic (typically 1% or 2% lidocaine) is infiltrated into the skin and deeper tissues along the planned needle tracts for both lesions, ensuring the patient feels minimal to no pain during the procedure.
• Tissue Acquisition: A tiny skin nick (1-2 mm) is made to facilitate the entry of the Trucut needle. Under continuous ultrasound visualization, the needle is advanced to the margin of the first lesion. The biopsy gun is activated, making a rapid clicking sound as it cuts and captures a core of tissue. This process is repeated 3 to 5 times for the first lesion to ensure adequate tissue volume. The needle is then redirected, or a second insertion is performed, to sample the second lesion in the same manner. Each set of specimens is immediately placed in separate, pre-labeled formalin vials to prevent cross-contamination.
• Post-Procedure Care: Once the samples are secured, direct manual pressure is applied to the biopsy sites for 10 to 15 minutes to achieve hemostasis. A sterile adhesive dressing and a cold compress are applied to minimize bruising and swelling. The entire procedure typically takes 30 to 45 minutes.

When is a Trucut Biopsy of 2 Lesions in Same Breast Performed?

Multiple Suspicious Breast Masses (BI-RADS 4 or 5)

When routine screening or diagnostic imaging (mammography or ultrasound) reveals two distinct masses within the same breast that are classified as BI-RADS 4 (suspicious abnormality) or BI-RADS 5 (highly suggestive of malignancy), a biopsy of both lesions is mandatory. Sampling only one lesion could lead to an incomplete diagnosis, as one mass might be benign while the other is malignant, or they may represent different histological subtypes of breast cancer.

Multifocal or Multicentric Breast Lesions

Physicians request a biopsy of two separate lesions to differentiate between multifocal disease (lesions within the same quadrant, often arising from the same ductal system) and multicentric disease (lesions in different quadrants, indicating independent primary tumors). This distinction is a critical factor in determining whether a patient is a candidate for breast-conserving surgery (lumpectomy) or requires a total mastectomy.

Persistent Palpable Lumps with Indeterminate Imaging

If a patient presents with two palpable lumps in the same breast, even if imaging findings are indeterminate or equivocal (BI-RADS 3), a Trucut biopsy may be performed. This is especially true if the patient has a high risk profile, such as a strong family history of breast or ovarian cancer, or carries BRCA1/BRCA2 genetic mutations, where clinical suspicion remains high despite non-definitive imaging.

Evaluation of New Lesions Near an Existing Diagnosed Mass

In patients with a known, previously diagnosed breast malignancy, the discovery of a second, adjacent lesion requires separate histological evaluation. Confirming whether the second lesion is an extension of the primary tumor, a satellite nodule, or an entirely unrelated benign entity (such as a fibroadenoma or cyst) is essential for accurate pathological staging (TNM classification) and surgical planning.

Distinguishing Synchronous Benign and Malignant Pathology

It is clinically common for benign and malignant conditions to coexist within the same breast. For instance, a patient may have a long-standing benign fibroadenoma alongside a newly developed invasive ductal carcinoma. Performing a Trucut biopsy on both lesions provides definitive histological proof of each mass, preventing unnecessary aggressive surgery on benign areas while ensuring prompt, targeted treatment for malignant zones.

What Does a Trucut Biopsy of 2 Lesions in Same Breast Detect?

A detailed histopathological analysis of the core biopsy samples can detect a wide spectrum of benign, high-risk, and malignant breast conditions. The primary pathological findings include:

• Invasive Ductal Carcinoma (IDC): The most common form of breast cancer, characterized by malignant epithelial cells invading through the basement membrane into the surrounding stroma.
• Invasive Lobular Carcinoma (ILC): A malignancy arising from the lobules, often presenting as a diffuse pattern of single-file cells (targetoid pattern) that can be difficult to detect on standard mammography.
• Ductal Carcinoma In Situ (DCIS): A non-invasive pre-cancerous condition where malignant cells are confined within the breast ducts without stromal invasion.
• Lobular Carcinoma In Situ (LCIS): A condition characterized by atypical cell proliferation within the breast lobules, serving as a marker for increased future risk of developing invasive breast cancer.
• Fibroadenoma: A highly common, benign fibroepithelial tumor characterized by a mixture of proliferating epithelial and stromal elements.
• Atypical Ductal Hyperplasia (ADH): A high-risk, borderline lesion showing some, but not all, features of DCIS, indicating an elevated risk of future malignancy.
• Atypical Lobular Hyperplasia (ALH): A benign but high-risk proliferation of atypical cells within the breast lobules.
• Fibrocystic Changes: A benign condition involving fluid-filled cysts, stromal fibrosis, and ductal hyperplasia, often fluctuating with the menstrual cycle.
• Fat Necrosis: A benign inflammatory reaction to local breast tissue injury or trauma, which can clinically and radiologically mimic a malignant mass.
• Sclerosing Adenosis: A benign lobular lesion characterized by an increased number of distorted and compressed acini surrounded by dense stromal fibrosis.
• Radial Scar / Complex Sclerosing Lesion: A benign fibroelastotic lesion with radiating ducts and lobules that can mimic the spicular appearance of malignancy on mammograms.
• Intraductal Papilloma: A benign, wart-like growth within the breast ducts that can cause bloody or serous nipple discharge.
• Phyllodes Tumor: A rare fibroepithelial tumor that can be classified as benign, borderline, or malignant based on stromal cellularity, mitotic activity, and margin characteristics.
• Granulomatous Mastitis: A chronic, non-infectious inflammatory condition of the breast that can form firm, painful masses mimicking carcinoma.
• Acute Breast Abscess / Mastitis: An infectious inflammatory process, common during lactation, characterized by neutrophilic infiltration and tissue necrosis.
• Columnar Cell Change / Hyperplasia: Benign alterations of the terminal duct lobular units (TDLUs) characterized by dilated acini lined by columnar epithelial cells.
• Flat Epithelial Atypia (FEA): A neoplastic alteration of the terminal duct lobular units, often associated with microcalcifications and considered a precursor to low-grade DCIS.
• Pseudoangiomatous Stromal Hyperplasia (PASH): A benign myofibroblastic proliferation forming slit-like spaces that simulate vascular channels.
• Apocrine Metaplasia: A benign change where normal cuboidal breast epithelial cells transform into larger cells with abundant eosinophilic cytoplasm.
• Diabetic Mastopathy: A rare, benign fibroinflammatory breast lesion occurring in patients with long-standing diabetes, presenting as hard, painless masses.
• Metastatic Disease to the Breast: Secondary malignant tumors originating from non-mammary primary sites, such as melanoma, lymphoma, or lung cancer.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, the processing of histopathology specimens is conducted under stringent quality control measures. Once the Trucut biopsy samples of the 2 breast lesions are received at the central histopathology department, they undergo formal fixation, tissue processing, paraffin embedding, microtome sectioning, and hematoxylin and eosin (H&E) staining. This meticulous process typically takes 3 to 5 working days. If advanced immunohistochemical (IHC) stains are required to determine hormone receptor status (ER, PR, HER2) or to differentiate between invasive and non-invasive disease, an additional 24 to 48 hours may be necessary.

Chughtai Lab offers convenient digital access to diagnostic reports. Patients and referring physicians can access, view, and download the verified histopathology reports online via the official Chughtai Lab website or through the My Chughtai App. Additionally, patients receive automated SMS notifications as soon as their reports are finalized and signed off by the consultant pathologist.

Trucut Biopsy Findings Overview

The following table outlines the key parameters evaluated during the histopathological examination of the biopsy specimens:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Tissue Architecture	Preserved lobular and ductal structures without stromal invasion.	Disrupted architecture, stromal invasion, cribriform patterns, or sheet-like cellular growth.
Epithelial Cell Morphology	Uniform, cohesive cuboidal to columnar cells with regular nuclei.	Pleomorphic cells, hyperchromatic nuclei, increased mitotic figures, or high nuclear grade.
Myoepithelial Cell Layer	Intact, continuous outer myoepithelial layer surrounding ducts and lobules.	Absence of the myoepithelial layer, indicating invasive carcinoma (e.g., IDC or ILC).
Stromal Component	Normal specialized and non-specialized breast stroma without atypia.	Stromal hypercellularity, myxoid changes, desmoplastic reaction, or elastosis.
Microcalcifications	Absent.	Present within benign acini, necrotic centers of DCIS, or malignant stroma.
Inflammatory Infiltrate	Minimal or absent.	Dense lymphocytic, neutrophilic, or granulomatous infiltration (e.g., mastitis).
Hormone Receptor Expression	Not applicable in benign tissue (or normal baseline expression).	Overexpression or absence of Estrogen (ER) and Progesterone (PR) receptors in malignant cells.
HER2/neu Protein Status	Negative (Score 0 or 1+).	Overexpressed (Score 3+) or equivocal (Score 2+), indicating the need for FISH testing.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient\’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Trucut Biopsy of 2 Lesions in Same Breast?

• Experienced Healthcare Professionals: The procedure is performed by highly skilled interventional radiologists and pathologists with extensive experience in breast diagnostics.
• Accurate Pathological Evaluation: Biopsy specimens are analyzed by senior consultant histopathologists specializing in breast pathology, ensuring highly accurate diagnoses.
• Advanced Ultrasound Guidance: High-resolution ultrasound systems are utilized to ensure precise needle localization and optimal sampling of both lesions.
• CAP-Compliant Standards: Chughtai Lab adheres to international quality control guidelines, ensuring reliable tissue processing and staining.
• Comprehensive IHC Panel: In cases of malignancy, a complete immunohistochemistry panel (ER, PR, HER2, Ki-67) is available in-house for rapid tumor profiling.
• Patient-Focused Care: The clinical team provides a compassionate, sterile, and comfortable environment to minimize patient anxiety during the procedure.
• Convenient Report Access: Reports can be easily accessed online via the My Chughtai App or the official website, facilitating quick clinical decision-making.
• Nationwide Network: With state-of-the-art diagnostic centers across Pakistan, patients can easily access follow-up services and consultation.